Guilin Sanjin Pharmaceutical Co., Ltd.

002275

CNE100000DY9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13.81 ^CNY	-8.42%		-9.44%	-4.69%

Apr. 25	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 04	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023

November 21, 2023 at 02:33 pm EST

Guilin Sanjin Pharmaceutical Co., Ltd. announced 2023 3rd quarter profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 3.00000000. Record date: 24 November 2023, Ex-date: 27 November 2023, Payment date: 27 November 2023.

Latest news about Guilin Sanjin Pharmaceutical Co., Ltd.

Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Guilin Sanjin Pharma to Sell Land, Buildings For 111 Million Yuan	Dec. 28	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index	23-09-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Board Elections	22-12-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO	22-08-31	MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO	22-08-19	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) dropped from S&P Global BMI Index	21-12-20	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index	21-09-20	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) dropped from FTSE All-World Index	21-09-20	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-09	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to FTSE All-World Index	21-03-22	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-23	CI
Shanghai Sanjin Biotechnology Co., Ltd. announced that it expects to receive CNY 75 million in funding from Guilin Sanjin Pharmaceutical Co., Ltd.	20-12-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

More charts

Company Profile

Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Guilin Sanjin Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.81

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUILIN SANJIN PHARMACEUTICAL CO., LTD.	-4.69%	1.12B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine